Disodium cromoglycate (DSCG) ( DrugBank: Cromoglycate )


1 disease
IDDisease name (Link within this page)Number of trials
85Idiopathic interstitial pneumonia2

85. Idiopathic interstitial pneumonia


Clinical trials : 598 Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-004025-40-NL
(EUCTR)
06/02/201511/12/2014Treatment of chronic cough with PA101.Treatment of Chronic Idiopathic Cough (CIC) and Chronic Cough in patients with Idiopathic Pulmonary Fibrosis (IPF) with PA101. - Treatment of chronic cough with PA101 Chronic Idiopathic Cough and Chronic Cough in Idiopathic Pulmonary Fibrosis
MedDRA version: 18.0;Level: LLT;Classification code 10066656;Term: Chronic cough;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Disodium Cromoglycate [cromolyn sodium]
Product Code: PA101
INN or Proposed INN: Not available
Other descriptive name: Disodium cromoglycate (DSCG)
Patara PharmaNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
48Netherlands;United Kingdom
2EUCTR2014-004025-40-GB
(EUCTR)
09/12/201406/01/2015Treatment of chronic cough with PA101.Treatment of Chronic Idiopathic Cough (CIC) and Chronic Cough in patients with Idiopathic Pulmonary Fibrosis (IPF) with PA101. - Treatment of chronic cough with PA101 Chronic Idiopathic Cough and Chronic Cough in Idiopathic Pulmonary Fibrosis
MedDRA version: 18.0;Level: LLT;Classification code 10066656;Term: Chronic cough;System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Disodium Cromoglycate [cromolyn sodium]
Product Code: PA101
Other descriptive name: Disodium cromoglycate (DSCG)
Patara PharmaNULLNot Recruiting Female: yes
Male: yes
48 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noNetherlands;United Kingdom